1387574-54-0
Chemical Structure
Lisavanbulin dihydrochloride
Synonym(s): BAL-101553 dihydrochloride
- CAS No.: 1387574-54-0
- Formula:C26H31Cl2N9O3
- Molecular Weight:588.49
IUPAC Name: (S)-2,6-diamino-N-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1H-benzo[d]imidazol-1-yl)acetyl)phenyl)hexanamide dihydrochloride
InChIKey: AOKATNWVGVIXOQ-TXEPZDRESA-N
SMILES: O=C(NC1=CC=C(C(CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N)=O)C=C1)[C@@H](N)CCCCN.Cl.Cl
Biological Activity: Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lisavanbulin dihydrochloride | 99.74% | Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Spriano F, et al. Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent[J]. bioRxiv, 2023: 2022.12. 31.521730.
- [2]. Joerger, M., et al., (2023). Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational new drugs, 41(2), 267–275. [Content Brief]
- [3]. Holdhoff, M., et al., (2024). Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma. Neuro-oncology advances, 6(1), vdae150. [Content Brief]
- [4]. Genoud, V., et al., (2021). Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). JCI insight, 6(18), e142980. [Content Brief]
Keywords
